A carer’s pledge to offer patients an informed choice between a novel drug or an injectable drug for the treatment of MDR-TB.
If you are directly or indirectly involved in the care of people with multidrug-resistant TB (MDR-TB), please consider endorsing this pledge to empower people with MDR-TB to choose between the use of a novel drug (currently bedaquiline or delamanid) or an injectable aminoglycoside drug as part of their MDR-TB regimen, based on all relevant information about known benefits and risks shared with them.